التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of hepatitis B virus transmission and antiviral therapy among hepatitis B surface antigen-positive pregnant women. |
| المؤلفون: |
Tekin Koruk, Suda, Batirel, Ayse, Kose, Sukran, Cetin Akhan, Sila, Aygen, Bilgehan, Tulek, Necla, Hatipoglu, Çigdem, Bulut, Cemal, Yıldız, Orhan, Sacligil, Cahide, Sirmatel, Fatma, Altunok, Elif |
| المصدر: |
Journal of Obstetrics & Gynaecology Research; Dec2015, Vol. 41 Issue 12, p1870-1876, 7p, 3 Charts |
| مصطلحات موضوعية: |
ANTIVIRAL agents, LAMIVUDINE, TENOFOVIR, HUMAN abnormalities, ANTIGENS, ASPARTATE aminotransferase, BIRTH weight, INFECTIOUS disease transmission, DNA, GESTATIONAL age, HEPATITIS B, HEPATITIS B vaccines, PATIENT aftercare, IMMUNOGLOBULINS, THIRD trimester of pregnancy, VIRAL antibodies, WOMEN, VIRAL load, ALANINE aminotransferase, TREATMENT effectiveness, FAMILY history (Medicine), DESCRIPTIVE statistics, DISEASE risk factors, THERAPEUTICS |
| مصطلحات جغرافية: |
TURKEY |
| مستخلص: |
Aim: The aimof the present studywas to assess the potential risk of hepatitis B virus (HBV) vertical transmission among Turkish parturient women and to evaluate the efficacy and safety of antiviral agents. Material and Methods: Data were collected retrospectively from 114 HBV-infected pregnant women and their infants in eight health institutions in Turkey. Results: The baseline characteristics of the women were: mean age, 28.3±5.2 years; alanine aminotransferase, 57.4±139.0 U/L; aspartate aminotransferase, 56.6±150.0 U/L; and HBV DNA, 8.3× 107±2.6×108 copies/mL. Family history of HBV infection was detected in 53.5% (n= 61). In total, 60 (52.6%) pregnant women received tenofovir (60.0%), lamivudine (33.3%) or telbivudine (6.7%) therapy at the median gestational age of 22.2±8.5 (1-36) weeks. All infants were vaccinated and hepatitis B immune globulin was administered, with 81 of them (71.1%) available for follow-up. After completion of HBV vaccination course, 71 (87.7%) infants had protective anti-HBs levels, three (3.7%) were hepatitis B surface antigen-positive, and seven (8.6%) were hepatitis B surface antigen-negative with nonprotective anti-HBs levels. Five of the infants had low gestational birthweight but no other birth defects were observed. Conclusion: According to our results, viral load may not be the only effecting factor for transmission of HBV to children of infected mothers. Pregnant women with high viral load should be followed-up closely during pregnancy. They should begin to take tenofovir or telbivudine, which are category B drugs for pregnancy, at the beginning of the third trimester at the latest. We need newtreatment strategies; and close follow-up ofmothers and children is another important issue. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Obstetrics & Gynaecology Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
